Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply

Lancet Oncol. 2022 Oct;23(10):e445. doi: 10.1016/S1470-2045(22)00563-0.

Authors

Patricia Pautier¹, Marie-Laure Tanguy², Baptiste Archambaud²

Affiliations

¹ Department of Medical Oncology, University Paris-Saclay, Gustave-Roussy, Villejuif 94805, France. Electronic address: patricia.pautier@gustaveroussy.fr.
² Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif 94805, France.

PMID: 36174626
DOI: 10.1016/S1470-2045(22)00563-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Doxorubicin / therapeutic use
Humans
Leiomyosarcoma* / drug therapy
Trabectedin

Substances

Doxorubicin
Trabectedin